A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Key claim: This early-phase trial measures the response rate of LY2784544 (a JAK2 inhibitor) in PV, ET, and MF patients, including those who are intolerant to or have failed ruxolitinib.
Abstract
The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.
Why this matters
Ruxolitinib failure/intolerance is one of the most clinically significant unmet needs in MPN treatment, and LY2784544’s evaluation across PV, ET, and MF in this population adds another JAK2-selective agent to a growing salvage landscape that includes AJ1-11095 (Type II JAK2i), PRT12396 (mutant-selective JAK2V617F), and flonoltinib. Capturing this finding helps the vault track the diversifying mechanistic strategies — selectivity, mutant-specificity, conformation-targeting — being deployed to overcome ruxolitinib resistance.